

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

October 2024

Vol. 52, No. 10

## Contents

### EDITORIAL

- Scientific Contributions to Drug Metabolism by Dr. Edward T. Morgan, the Recipient of the Bernard B. Brodie Award in Drug Metabolism and Disposition in 2024—Editorial 1037  
*Xiao-Bo Zhong and Yurong Lai*

### MINIREVIEW

- Shining a Light on Inflammation as a Critical Modulator of Drug Metabolism 1039  
*Edward T. Morgan*

### ARTICLES

- ☐ Proof of Concept of an All-in-One System for Measuring Hepatic Influx, Egress, and Metabolic Clearance Based on the Extended Clearance Concept 1048  
*Julia A. Schulz Pauly, Elizabeth Sande, Mei Feng, Yue-Ting Wang, David M. Stresser, and John Cory Kalvass*
- ☐ Predicting Clearance with Simple and Permeability-Limited Physiologically Based Pharmacokinetic Frameworks: Comparison of Well-Stirred, Dispersion, and Parallel-Tube Liver Models 1060  
*Swati Nagar, Rachel Parise, and Ken Korzekwa*
- Utility of Chimeric Mice with Humanized Livers for Predicting Hepatic Organic Anion-Transporting Polypeptide 1B–Mediated Clinical Drug–Drug Interactions 1073  
*Bo Feng, Guiqing Liang, Craig Zetterberg, Shaolan Li, Hui Huang, John Williams, Hong Gao, Yoshio Morikawa, and Sanjeev Kumar*
- ☐ Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2'-O-Glucuronide Formation as a Selective UGT2B4 Probe Reaction 1083  
*Kimberly Lapham, Nicholas Ferguson, Mark Niosi, and Theunis C. Goosen*
- Development of a Novel HEK293 Cell Model Lacking *SLC29A1* to Study the Pharmacology of Endogenous *SLC29A2*-Encoded Equilibrative Nucleoside Transporter Subtype 2 1094  
*Nayyar Shahid, Christopher Cromwell, Basil P. Hubbard, and James R. Hammond*
- Methyltransferase Like-3–Mediated N6-Methyladenosine Modification of Long Noncoding RNA Hepatocyte Nuclear Factor 1a Antisense RNA 1/Hepatocyte Nuclear Factor 4a Antisense RNA 1 Regulates Cytochrome P450 Enzyme Expression 1104  
*Yihang Yu, Jingya Wang, Zaihuan Xiong, Anqi Du, Xiaofei Wang, Yiting Wang, Shengna Han, Pei Wang, and Lirong Zhang*
- ☐ Metabolism and Excretion of [<sup>14</sup>C]Mobocertinib, a Selective Covalent Inhibitor of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations, in Healthy Male Subjects 1115  
*Hao Chen, Abhi Shah, Suguru Kato, Robert Griffin, Steven Zhang, Sandeepraj Pusalkar, Lawrence Cohen, Yuexian Li, Swapan K. Chowdhury, and Sean Xiaochun Zhu*

☐ Supplemental material is available at [dmd.aspetjournals.org](http://dmd.aspetjournals.org).

*About the cover:* “METTL3 mediates the stability of lncRNAs HNF1A-AS1 and HNF4A-AS1, and ultimately regulates the expression of drug-metabolizing enzymes through the TF-CYP axis.” See the article by Zhang et al. ([dx.doi.org/10.1124/dmd.124.001832](https://doi.org/10.1124/dmd.124.001832)).

□ The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans

1124

*Jonathan N. Bauman, Angela C. Doran, Gabrielle M. Gualtieri, Brian Hee, Timothy Strelevitz, Matthew A. Cerny, Christopher Banfield, Anna Plotka, Xiaoxing Wang, Vivek S. Purohit, and Martin E. Dowty*